Status:
COMPLETED
Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium
Lead Sponsor:
VA New York Harbor Healthcare System
Conditions:
Kidney Stones
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Thiazide diuretics will be more effective in lowering urine calcium excretion if taken at night as compared to the daytime. It will therefore be more effective in reducing kidney stone recurrence in n...
Detailed Description
The study will be divided into three phases for every single patient, investigators will study 15-20 stone formers who have previously documented elevated urine calcium excretion, with a plan to measu...
Eligibility Criteria
Inclusion
- Patients with recurrent calcium kidney stones (at least 2 episodes) and either a higher urine calcium excretion (urine Ca \>200 mg/d or \> 4 mg/kg body weight) or,
- In patients who currently take a thiazide diuretic, a history of elevated urine calcium prior to medication use;
- Also capable of signing consent and doing 24-hour urine collections repeatedly.
Exclusion
- Patients with primary hyperparathyroidism, renal tubular acidosis, chronic kidney disease (serum creatinine \> 1.5 mg/dl), inflammatory bowel disease, gout,
- Patients taking thiazides with a history of hypertension,
- Patients with baseline systolic blood pressure less than 110mmHg
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2017
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02711670
Start Date
February 1 2014
End Date
June 1 2017
Last Update
April 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA New York Harbor Healthcare System
New York, New York, United States, 10010